Navigation Links
A novel target for therapeutics against Staph infection
Date:11/27/2008

Researchers at the Texas A&M Health Science Center Institute of Biosciences and Technology, and the University of Edinburgh have uncovered how a bacterial pathogen interacts with the blood coagulation protein fibrinogen to cause methicillin-resistant Staphylococcus aureus (MRSA) infections, a finding that could aid in developing therapeutics against the potentially deadly disease. Their work appears November 28 in the open-access journal PLoS Pathogens.

Once occurring more commonly in healthcare facilities, but now affecting segments of the general population, MRSA is a bacterial pathogen responsible for a range of diseases from mild skin infection to life-threatening sepsis. Even with antibiotics, these infections can still be fatal.

Senior author Magnus Hk, Ph.D. and his colleagues carried out biochemical and structural studies to determine the binding mechanism of clumping factor A (ClfA), a surface protein that plays an important role in the pathogenesis of S. aureus. The group found that ClfA binds to the blood-clotting protein fibrinogen (Fg) at a site that is also responsible for inducing platelet activation and thrombosis (clot inside a blood vessel).

The results show significant structural differences in how staphylococcal and platelet receptor proteins recognize fibrinogen. By exploiting this difference in recognition, the researchers show that agents could be designed that inhibit the ClfAFg interaction but do not interfere with the interaction of Fg with the platelet integrin, therefore avoiding unwanted side effects on the circulatory system.


'/>"/>

Contact: Mary Kohut
Press@plos.org
415-568-3457
Public Library of Science
Source:Eurekalert

Page: 1

Related biology news :

1. Corn researchers discover novel gene shut-off mechanisms
2. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions
3. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
4. GEN reports on novel tools for deciphering biological networks
5. Novel publishing approach puts textbook in more hands
6. Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer
7. Childrens National researchers develop novel anti-tumor vaccine
8. LIAI launches new division to look at novel approaches to heart disease and inflammation
9. Conaway Lab identifies novel mechanism for regulation of gene expression
10. Scientists identify novel inhibitor of human microRNA
11. Using novel tool, UD researchers dig through cell trash and find treasure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
Breaking Biology News(10 mins):
(Date:5/18/2016)... Calif. (PRWEB) , ... May 18, 2016 , ... ... awarded the Luis Villalobos Award to Cognition Therapeutics at the annual ACA Summit last ... company that is financed by one of ACA’s member angel groups. It is the ...
(Date:5/18/2016)... , May 18, 2016 The Biotech ... does not mean that there are no opportunities ahead. Today, ... Inc. (NASDAQ: THLD ), Seattle Genetics Inc. (NASDAQ: ... ), and Ophthotech Corp. (NASDAQ: OPHT ). Sign ... at: http://www.activewallst.com/ Threshold Pharmaceuticals ...
(Date:5/18/2016)... ... 18, 2016 , ... Every day, more than 5,400 ER ... Costing more than $56 billion in direct costs annually, asthma remains a critical ... the suffering associated with uncontrolled asthma can be overwhelmingly disproportionate and better managed,” ...
(Date:5/18/2016)... ... ... Ryan Benton was diagnosed with Duchenne Muscular Dystrophy (DMD) at the age ... DMD is a relatively common progressive genetic disorder, which causes aggressive deterioration of the ... He met with the founder of the Stem Cell Institute in Panama ...
Breaking Biology Technology: